264 related articles for article (PubMed ID: 37746249)
1. Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia.
Feng L; Zhang PY; Gao W; Yu J; Robson SC
Front Oncol; 2023; 13():1244280. PubMed ID: 37746249
[TBL] [Abstract][Full Text] [Related]
2. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
[TBL] [Abstract][Full Text] [Related]
3. FBP1-Altered Carbohydrate Metabolism Reduces Leukemic Viability through Activating P53 and Modulating the Mitochondrial Quality Control System In Vitro.
Xu Y; Tran L; Tang J; Nguyen V; Sewell E; Xiao J; Hino C; Wasnik S; Francis-Boyle OL; Zhang KK; Xie L; Zhong JF; Baylink DJ; Chen CS; Reeves ME; Cao H
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232688
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling.
Lu J; Dong Q; Zhang S; Feng Y; Yang J; Zhao L
Cancer Sci; 2023 Aug; 114(8):3287-3300. PubMed ID: 37272257
[TBL] [Abstract][Full Text] [Related]
5. Stromal cells promote chemoresistance of acute myeloid leukemia cells via activation of the IL-6/STAT3/OXPHOS axis.
Hou D; Wang B; You R; Wang X; Liu J; Zhan W; Chen P; Qin T; Zhang X; Huang H
Ann Transl Med; 2020 Nov; 8(21):1346. PubMed ID: 33313091
[TBL] [Abstract][Full Text] [Related]
6. DNA damage to bone marrow stromal cells by antileukemia drugs induces chemoresistance in acute myeloid leukemia via paracrine FGF10-FGFR2 signaling.
Yu S; Ye J; Wang Y; Lu T; Liu Y; Liu N; Zhang J; Lu F; Ma D; Gale RP; Ji C
J Biol Chem; 2023 Jan; 299(1):102787. PubMed ID: 36509141
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dependencies of acute myeloid leukemia stem cells.
Shi X; Feng M; Nakada D
Int J Hematol; 2024 May; ():. PubMed ID: 38750343
[TBL] [Abstract][Full Text] [Related]
9. Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis.
Egan G; Schimmer AD
Trends Cell Biol; 2023 Jun; 33(6):455-462. PubMed ID: 36481232
[TBL] [Abstract][Full Text] [Related]
10. 2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies.
Raimondi V; Ciotti G; Gottardi M; Ciccarese F
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740380
[TBL] [Abstract][Full Text] [Related]
11. Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment.
Tabe Y; Konopleva M
Cancer Drug Resist; 2023; 6(1):138-150. PubMed ID: 37065866
[TBL] [Abstract][Full Text] [Related]
12. IL-6 promotes chemoresistance via upregulating CD36 mediated fatty acids uptake in acute myeloid leukemia.
Zhang Y; Guo H; Zhang Z; Lu W; Zhu J; Shi J
Exp Cell Res; 2022 Jun; 415(1):113112. PubMed ID: 35346671
[TBL] [Abstract][Full Text] [Related]
13. Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia.
Takam Kamga P; Bassi G; Cassaro A; Midolo M; Di Trapani M; Gatti A; Carusone R; Resci F; Perbellini O; Gottardi M; Bonifacio M; Nwabo Kamdje AH; Ambrosetti A; Krampera M
Oncotarget; 2016 Apr; 7(16):21713-27. PubMed ID: 26967055
[TBL] [Abstract][Full Text] [Related]
14. Targeting mitochondrial metabolism in acute myeloid leukemia.
Rex MR; Williams R; Birsoy K; Ta Llman MS; Stahl M
Leuk Lymphoma; 2022 Mar; 63(3):530-537. PubMed ID: 34704521
[TBL] [Abstract][Full Text] [Related]
15. Berberine targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia with IDH1 mutation.
Huang Z; Shen Y; Liu W; Yang Y; Guo L; Yan Q; Wei C; Guo Q; Fan X; Ma W
Chin J Nat Med; 2023 Feb; 21(2):136-145. PubMed ID: 36871981
[TBL] [Abstract][Full Text] [Related]
16. Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia.
Aroua N; Boet E; Ghisi M; Nicolau-Travers ML; Saland E; Gwilliam R; de Toni F; Hosseini M; Mouchel PL; Farge T; Bosc C; Stuani L; Sabatier M; Mazed F; Larrue C; Jarrou L; Gandarillas S; Bardotti M; Picard M; Syrykh C; Laurent C; Gotanègre M; Bonnefoy N; Bellvert F; Portais JC; Nicot N; Azuaje F; Kaoma T; Joffre C; Tamburini J; Récher C; Vergez F; Sarry JE
Cancer Discov; 2020 Oct; 10(10):1544-1565. PubMed ID: 32641297
[TBL] [Abstract][Full Text] [Related]
17. DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming.
Yang X; Wang X; Yang Y; Li Z; Chen Y; Shang S; Wang Y
J Transl Med; 2023 Jul; 21(1):481. PubMed ID: 37464424
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy.
You R; Hou D; Wang B; Liu J; Wang X; Xiao Q; Pan Z; Li D; Feng X; Kang L; Chen P; Huang H
J Leukoc Biol; 2022 Aug; 112(2):299-311. PubMed ID: 34927743
[TBL] [Abstract][Full Text] [Related]
19. A Leukemic Target with a Thousand Faces: The Mitochondria.
Maffeo B; Panuzzo C; Moraca A; Cilloni D
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685874
[TBL] [Abstract][Full Text] [Related]
20. VEGFR2-Mediated Reprogramming of Mitochondrial Metabolism Regulates the Sensitivity of Acute Myeloid Leukemia to Chemotherapy.
Nóbrega-Pereira S; Caiado F; Carvalho T; Matias I; Graça G; Gonçalves LG; Silva-Santos B; Norell H; Dias S
Cancer Res; 2018 Feb; 78(3):731-741. PubMed ID: 29229602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
